Read More

Turnaround For Pharvaris Since FDA Clinical Hold – Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks

Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results as an oral preventative treatment for people living with 

PHVS

Read More

LuxUrban Hotels And Company’s Chairman And Co-CEO Mutually Agree To Cancel $10M Financing Arrangement In Light Of Ongoing Discussions To Enhance Access To Non-Dilutive Capital

Chairman and Co-CEO has Ceased Further Sales of the Company's Common Stock Associated with the Now Cancelled Financing ArrangementLuxUrban Hotels Inc. (or the "Company") (NASDAQ:LUXH), which utilizes an asset-light

LUXH